Class / Patent application number | Description | Number of patent applications / Date published |
424150100 | Binds bacterium or component thereof or substance produced by said bacterium | 36 |
20090053235 | Use of alpha-toxin for treating and preventing staphylococcus infections - Vaccines comprising an | 02-26-2009 |
20090214566 | Protective anti-glucan antibodies with preference for beta-1,3- glucans - Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with | 08-27-2009 |
20090220522 | Detoxified Endotoxin Vaccine and Adjuvant and Uses thereof - The present invention describes a detoxified Gram negative J5 core lipopolysaccharide/group B meningococcal outer membrane protein complex vaccine given in conjunction with CpG 7909 adjuvant. This vaccine composition can be used for either active or passive immunization of mammals for the prevention or treatment of sepsis and infection with Gram negative bacteria. The addition of CpG to the vaccine was shown to markedly increase the antibody response in mice. Furthermore, the ability of the endotoxin vaccine in protecting against Gram-negative bacteria such as | 09-03-2009 |
20090274704 | Anti-staphylococcus aureus antibodies - A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds a | 11-05-2009 |
20090324606 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 12-31-2009 |
20100003263 | MONOCLONAL ANTIBODIES TO ANTHRAX PROTECTIVE ANTIGEN - The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a | 01-07-2010 |
20100047252 | ANTIBODY WITH PROTEIN A SELECTIVITY - Monoclonal antibodies, and antigen binding fragments thereof, which bind to Protein A of | 02-25-2010 |
20100150934 | BOTULINUM ANTITOXIN COMPOSITIONS AND METHODS - This invention provides | 06-17-2010 |
20100183623 | MONOCLONAL ANTIBODIES RECOGNIZING A COAGULASE-NEGATIVE STAPHYLOCOCCAL PROTEIN - Monoclonal antibodies which can bind to the SdrF protein of | 07-22-2010 |
20100196391 | SHIGELLA IPAD PROTEIN AND ITS USE AS A VACCINE AGAINST SHIGELLA INFECTION - The present invention relates to compositions and methods for blocking entry of | 08-05-2010 |
20100233181 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 09-16-2010 |
20100233182 | Antibodies against Clostridium difficile toxins and uses thereof - Antibodies that specifically bind to toxins of | 09-16-2010 |
20100247546 | OPSONIC MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR LIPOTEICHOIC ACID OF GRAM POSITIVE BACTERIA - The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them. | 09-30-2010 |
20100291100 | Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions - The present invention provides genes encoding novel microbial proteins (i.e., for example, exosporium genes and proteins) that mediate the attachment of microbial spores to surfaces. Specific fragments of these microbial spore proteins may be utilized to inhibit the attachment of microbial spores to surfaces, thereby providing an infection control agent. The invention provides recombinant expression vectors comprising genes encoding exosporium proteins, as well as host cells containing these expression vectors. Further provided herein are screening methods for identifying infection control compositions comprising exosporium proteins that inhibit bacterial spore attachment to either bodily tissues or solid surfaces. Additionally, the invention provides for the use of nucleic acid inhibitors of exosporium protein expression by hybridizing with nucleic acid sequences encoding exosporium proteins as well as with exosporium mRNA. The invention further describes monoclonal and polyclonal antibodies having affinity for exosporium proteins. | 11-18-2010 |
20100322944 | Anti-bacterial antibodies - A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A. | 12-23-2010 |
20110002937 | METHOD OF MAKING HYBRID CELLS THAT EXPRESS USEFUL ANTIBODIES - This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention. | 01-06-2011 |
20110110954 | Anthrax compositions and methods of use and production - Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by | 05-12-2011 |
20110117104 | MONOCLONAL ANTIBODY SPECIFIC TO ANTHRAX TOXIN - Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin. | 05-19-2011 |
20110150896 | Antibody against PCRV - Provided is an effective means for therapy of infection, particularly infection with | 06-23-2011 |
20110274700 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as | 11-10-2011 |
20120082677 | COMPOSITIONS FOR THE TREATMENT OF HCV AND HBV - Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of hepatitis C infected patients. | 04-05-2012 |
20120100151 | Antibodies or Fragments Thereof Directed Against a Staphylococcus Aureus Epitope of ISAA or ISAB - The invention concerns antibodies or fragments thereof that are directed against a | 04-26-2012 |
20120114662 | HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN - Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 05-10-2012 |
20120195907 | MONOCLONAL ANTIBODIES AGAINST THE PBP2-A PROTEIN AND HOMOLOGOUS SEQUENCES FOR THE TREATMENT OF INFECTIONS BY AND IMMUNODIAGNOSTICS OF BACTERIA OF THE FIRMICUTES PHYLUM - The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant | 08-02-2012 |
20120201829 | Human Monoclonal Antibody Against S. Aureus Derived Alpha-Toxin and Its Use in Treating or Preventing Abscess Formation - The present invention includes a human monoclonal antibody specific for the alpha-toxin of | 08-09-2012 |
20120282268 | Novel Cell Wall Components of Enterococci and Uses Thereof - The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection. | 11-08-2012 |
20120288508 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 11-15-2012 |
20130045211 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA - The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption. | 02-21-2013 |
20130236469 | VACCINE AGAINST STREPTOCOCCAL INFECTIONS BASED ON RECOMBINANT PROTEINS - An antigenic composition comprises several antigenic components derived from antigens of | 09-12-2013 |
20140056908 | CLOSTEROVIRUS-BASED NUCLEIC ACID MOLECULES AND USES THEREOF - The present invention relates to novel nucleic acid molecules for producing target polypeptides in plant cells. More specifically, the novel nucleic acid molecules comprise a minireplicon derived from a Closteroviridae virus and heterologous polynucleotides encoding the target polypeptides. Also provided are compositions comprising the target polypeptides and uses thereof. | 02-27-2014 |
20140286960 | STAPHLOCOCCUS AUREUS ALPHA-HEMOLYSIN ANTIBODIES - Compositions and methods for the treatment or prevention of | 09-25-2014 |
20140356375 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
20140356376 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
20150017181 | PREVENTION OF INFECTION - The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by | 01-15-2015 |
20150064198 | Enhancing Immunity to Tuberculosis - The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. | 03-05-2015 |
20160145324 | Antibodies Directed to Bacillus Anthracis Protective Antigen - This disclosure generally relates to therapeutic antibodies for treating | 05-26-2016 |